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Background: Concurrent chemoradiotherapy (CCRT) for locore-
gionally advanced esophageal or gastroesophageal junction cancer
produces high locoregional control rates but suboptimal distant
metastatic control (DMC) and overall survival. This phase II study
added gefitinib (G) to our previously tested CCRT regimen in an
effort to improve these outcomes.
Methods: Eligibility required T3, N1, or M1a esophageal or gas-
troesophageal junction squamous cell or adenocarcinoma staged by
esophageal ultrasound and positron emission tomography/computed
tomography. Four-day continuous intravenous infusions of cisplatin
(20 mg/m2/d) and fluorouracil (1000 mg/m2/d) began on day 1 of
preoperative radiation (30 Gy and 1.5 Gy bid). Surgery followed in
4 to 6 weeks, and an identical course of CCRT 6 to 10 weeks
postoperatively. G 250 mg/d was given with preoperative CCRT for
4 weeks and restarted with postoperative therapy for 2 years. Results
were retrospectively compared with our historical series of 93
patients given CCRT without G.
Results: Between April 2003 and July 2006, 80 patients were enrolled.
Patient and tumor characteristics were similar to our historical series. G
did not increase toxicity except for development of rash in 42 (53%)
and diarrhea in 44 (55%) 3-year Kaplan-Meier estimates (G versus
non-G treated patients) included: overall survival (42% versus 28%,
p 0.06), DMC (40% versus 32%, p 0.33), and locoregional control
(76% versus 77%, p  0.74). Intolerance for G maintenance occurred
in 48% of patients. Patients who experienced G related diarrhea ap-
peared to have improved outcomes.
Conclusions: Although G did not worsen CCRT toxicity, mainte-
nance therapy proved difficult. This contemporary cohort of patients
enjoyed superior survival, which does not solely reflect a decrease in
DMC and merits further investigation.
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(J Thorac Oncol. 2010;5: 229–235)
Esophagus and gastroesophageal junction (GEJ) cancer is alethal malignancy rapidly increasing in incidence. As in
most solid tumors, survival is predicted by disease stage at
presentation. In early stage disease, surgical resection alone is
often curative. For patients with locoregionally advanced
disease, however, fewer than 20% are cured with surgical
resection alone, and the optimal treatment approach is not
well defined.1,2 Over the last 20 years, clinical trials have
suggested that the addition of perioperative chemotherapy or
chemoradiation to surgery may improve survival.3–8
Since 1999 at the Cleveland Clinic, patients with lo-
coregionally advanced esophagus or GEJ cancer have been
treated with perioperative multiagent chemotherapy and split
course radiation. Using this regimen, we achieved a 3-year
locoregional control (LRC) rate of 86% but an overall sur-
vival (OS) of only 28%, with most patients developing distant
metastasis.9 This pattern of treatment failure suggests the
need for better systemic therapy.
The epidermal growth factor receptor (EGFR) is over-
expressed in 60 to 70% of esophageal squamous cell carci-
nomas,10,11 and 30 to 70% of distal esophageal or GEJ
adenocarcinomas.12,13 This suggests a role for the clinically
available monoclonal antibody EGFR inhibitors cetuximab
and panitumimab or the oral tyrosine kinase EGFR inhibitors
gefitinib (G) and erlotinib. Limited phase II data in patients
with metastatic esophageal cancer have suggested drug ac-
tivity, with reported objective response rates of approxi-
mately 10% and disease control rates of 30%,13,14 similar to
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our Cleveland Clinic experience.15 These agents’ relatively
favorable toxicity profile and demonstrated activity in meta-
static disease suggested to us that their addition to our
definitive perioperative concurrent chemoradiotherapy regi-
men might favorably impact the high rate of distant meta-
static failure and led to the development of this trial. The goal
of this trial was to examine OS and distant metastatic control
(DMC) among patients with locally advanced esophageal or
gastroesophageal cancer treated with perioperative concurrent
chemotherapy radiation and G followed by maintenance G.
PATIENTS AND METHODS
Study Design
This is an open label phase II study of patients with
locoregionally advanced esophageal or GEJ carcinoma. Sup-
port for this research and the experimental drug (G) was
provided by AstraZeneca Pharmaceuticals (Reference num-
ber: IRUSIRES0250). The primary objective was to deter-
mine OS and DMC among patients enrolled. Secondary
objectives included toxicity, pathologic response rates, and
long-term G tolerance. The results were retrospectively com-
pared with a historical cohort of 93 patients, with identical
eligibility criteria, who were treated on our previous phase II
protocol with the same concurrent chemoradiotherapy and
surgery regimen without G.9
Patients
Patients with previously untreated, histologically con-
firmed squamous cell or adenocarcinoma of the esophagus or
GEJ were eligible for participation. Enrollment required normal
renal, bone marrow, and hepatic function; adequate cardiac and
pulmonary reserve to undergo surgical resection; and an Eastern
Cooperative Oncology Group performance status of 0 or 1.
A thoracic surgeon, radiation oncologist, and medical
oncologist evaluated each patient before enrollment. A medical
history, physical examination, complete blood count, serum
chemistries with hepatic function panel, chest radiograph, and
pulmonary function testing were obtained. Disease staging in-
cluded an esophagogastroduodenoscopy with endoscopic ultra-
sound, computed tomography (CT) of the chest, abdomen and
pelvis, and whole body positron emission tomographic (PET)
scanning. Bronchoscopy was performed in patients whose
symptoms, tumor extent, or location suggested a risk of airway
involvement. The American Joint Committee on Cancer 2002
staging system was used to assign a clinical disease stage.16
Participation required T3, N1, or M1a disease. Patients with
hematogenous metastases (M1b) were ineligible.
This protocol was approved and reviewed yearly by the
Cleveland Clinic Institutional Review board. All patients
signed written informed consent.
Treatment
Figure 1 illustrates the treatment schema. Concurrent
chemoradiation was administered in a split course fashion
before and after surgery. Preoperative radiotherapy was de-
livered in 1.5 cGy fractions, twice daily over 12 days to a
dose of 30 Gy. A 96-hour continuous intravenous infusion of
cisplatin (20 mg/m2/d) and fluorouracil (1000 mg/m2/d) was
begun on the first day of radiation. The delivery of two drugs,
both by means of continuous intravenous infusion required
and was facilitated by hospitalization on a dedicated inpatient
chemotherapy administration service at our institution. G 250
mg daily orally was started on the first day of concurrent
chemoradiation and continued for 4 weeks.
Radiation therapy was administered using 6 mega-
voltage photon beams generated by a linear accelerator.
Preoperative radiation fields encompassed the primary tumor,
involved nodal areas, and regional lymphatic areas at risk for
microscopic disease involvement. A 5 cm cephalocaudal and
2 to 2.5 cm radial margin were applied in treating the primary
tumor. The at-risk nodal areas treated in patients with prox-
imal esophageal cancers were the supraclavicular, lower
cervical, and upper mediastinal areas. For mid esophageal
tumors, all mediastinal lymph node stations were irradiated.
All lower mediastinal nodal stations and celiac lymph nodes
were irradiated in patients with distal or GEJ primary tumors.
For two-dimensional planning, dosimetry was generated at
the central axis of the field, the center of the target volume,
and at planes 1.0 and 1.5 cm inside the superior and inferior
margins of the treatment fields. For three-dimensional plans,
gross tumor volume with lymph nodes at risk was enclosed in
a planning tumor volume covered by 95% isodose line.
Tissue inhomogeneity corrections were not used. Postopera-
tive treatment volumes were planned for each patient and
replicated preoperative field coverage of areas at risk.
Patients were evaluated weekly during radiation ther-
apy to both monitor and treat any toxicities that developed.
Any febrile episode during neutropenia necessitated hospital-
ization for intravenous antibiotics. Patients with poor oral
intake from mucositis or dysphagia resulting in dehydration
were also hospitalized. Four to six weeks after completion of
the first course of radiation therapy, patients were restaged to
confirm the absence of distant metastases and if appropriate
were taken to surgery.
In general, a near-complete esophagectomy was planned
and accomplished through simultaneous left thoracoabdominal
and left neck incisions. In patients with upper or midthoracic
tumors, at risk for involvement of the airway or the aortic arch,
a right thoractomy followed by a midline laparotomy and left
neck incision for reconstruction was preferred. Surgical margins
were examined intraoperatively with the goal of achieving dis-
ease-free proximal, distal, and soft tissue margins of resection.
Lymphadenectomy was performed in a continuous fashion and
FIGURE 1. Treatment schema.
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extended from the aortic arch to the celiac axis when a left-sided
thoractomy and left neck incision were made. Alternatively,
lymph node dissection was extended to the apex of the right
chest in the setting of a right-sided thoracotomy. The stomach
was used for reconstruction, and the anastomosis was per-
formed, when possible, at the thoracic inlet to place it outside the
radiation fields. For GEJ cancers with extensive gastric involve-
ment requiring gastrectomy, the esophagojejunal anastomosis
was constructed in the left chest above the inferior pulmonary
vein but within the radiation fields.
The postoperative stage was determined after patho-
logic examination of the resected specimen. A pathologic
response to induction chemoradiation required improvement
in T, N, or M1a designation without a reciprocal increase in
any other descriptor.
Postoperative chemoradiation was begun 6 to 10 weeks
after surgical resection using a regimen identical to the preop-
erative treatment. Postoperative radiation was delivered to the
tumor bed. In patients with positive margins, the anastomosis
was included in the treatment field. Patients completing preop-
erative therapy, who could not undergo surgery either for med-
ical reasons or because of locoregionally unresectable disease
identified at surgery, also received postoperative therapy in this
fashion. G 250 mg daily was restarted on the first day of
postoperative chemoradiation and continued for a planned
2-year course of maintenance therapy. Most patients develop
distant disease recurrence in the first 2 years after completion of
multimodality treatment, thus the 24-month duration of mainte-
nance therapy, similar to trials using maintenance G after defin-
itive chemoradiation for locally advanced head and neck squa-
mous cell carcinoma.17,18
After completion of radiation therapy, patients were
followed up every 3 months for evidence of disease recur-
rence and to monitor any treatment-related toxicities. Radio-
graphic imaging and endoscopic examinations were per-
formed if clinically indicated. Any disease recurrence was
characterized as locoregional, distant, or both.
Statistical Considerations
In our phase II study that examined this perioperative
chemoradiotherapy regimen without G, we observed a me-
dian OS of 15 months and a median DMC of 13 months. A
sample size of 80 patients was needed to have 78% power to
detect an increase in the median OS to 24 months and 85%
power to detect an increase to 25 months. This sample size
also had 78% and 85% power to identify an increase in DMC
to 20 and 21 months, respectively. It is important to point out
that this was not a prospective randomized trial comparing
perioperative concurrent chemoradiation with and without G.
However, for the purpose of hypothesis generation retrospec-
tive comparisons have been made with our historical series of
patients treated on a previously published phase II trial with
identical eligibility criteria, using the same perioperative
concurrent chemoradiation regimen without G.
Categorical variables are summarized as frequency
counts and percentages and compared between studies using
the 2 test. Continuous variables are summarized as the
median and range and compared using the t test or Wilcoxon
rank sum test. Four outcomes were assessed: freedom from
recurrence (FFR), LRC, DMC, and OS. The events defining
these outcomes were any recurrence for FFR, locoregional
recurrence for LRC, distant recurrence for DMC, and all-
cause mortality for OS. All outcomes were calculated relative
to the start of the first course of chemoradiotherapy. Out-
comes were estimated using the Kaplan-Meier method and
compared between studies using the log-rank test.
Additional analyses were performed among patients in
this study. G intolerance was assessed and defined by the event
of G discontinuation for reasons unrelated to disease progression
or recurrence. Exploratory Kaplan-Meier analyses were also
performed examining the study outcomes for pathologic stage,
pathologic response, and G-related rash or diarrhea.
Analyses were done using SAS software (SAS Insti-
tute, Inc., Cary, NC). A p value of0.05 was used to indicate
statistical significance, and unless otherwise noted all statis-
tical tests were two sided.
RESULTS
Between April 2003 and July 2006, 80 patients were
enrolled. Table 1 details patient and tumor characteristics, which
were, in general, very similar to our previously reported cohort




(n  93) p
Median age (range), yr 58 (33–75) 59 (35–76) 0.44
Gender (%)
Male 73 (91) 80 (86) 0.28
Race (%) 0.54
White 75 (94) 89 (96)
African American 4 (5) 4 (4)
Asian 1 (1) 0
Barrett’s esophagus (%) 35 (44) 30 (32) 0.12
Histology (%) 0.09
Squamous cell carcinoma 4 (5) 13 (14)
Adenocarcinoma 75 (94) 77 (83)
Adenosquamous carcinoma 1 (1) 3 (3)
Tumor location (%) 0.83
Proximal esophagus 1 (1) 2 (2)
Mid esophagus 5 (6) 8 (9)
Distal esophagus 28 (35) 35 (38)
GEJ 46 (58) 48 (52)
Preoperative TNM stage (%) 0.10
T3N0M0 15 (19) 29 (31)
T2N1M0 11 (14) 3 (3)
T3N1M0 30 (38) 43 (46)
T4N0M0 1 (1) 0
T4N1M0 0 1 (1)
T3N0M1a 1 (1) 0
T2N1M1a 4 (5) 0
T3N1M1a 18 (22) 15 (16)
T4N1M1a 0 2 (2)
T3 or N1 56 (70) 75 (81)
T4 or M1a 24 (30) 18 (19)
GEJ, gastroesophageal junction; TNM, tumor, node, metastasis; G, gefitinib.
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treated without G. The median age was 58 years (range 33–75
years) with a predominance of white (94%) males (91%) with
adenocarcinoma (94%). The primary tumor was almost always
located in the distal esophagus (35%) or the GEJ (58%); 35
patients (44%) had evidence of Barrett esophagus. Pretreatment
clinical staging was similar when the current and historical
cohorts are compared. Twenty-three patients (29%) had M1a
disease. All patients on both clinical trials received all the
planned chemotherapy and radiation.
The surgical outcomes are displayed in Table 2. Seventy-
three patients (91%) underwent surgical resection on the current
trial. Seven patients did not undergo surgery; four due to the
development of metastatic disease before surgery, one due to
hepatic cirrhosis identified during abdominal exploration, one
due to a pneumonia compromising pulmonary function, and one
due to protracted recovery after preoperative therapy. Tumor
margins were positive in eight patients (11%). Postoperative
complications developed in 33 patients (45%) including a
wound infection in six patients, chyle leak in five, pneumonia in
three, and pleural effusion in three. Although we reported four
postoperative deaths (5%) in our historical series without G,
there were no postoperative deaths in the current series.
Pathologic response rates did not differ between these
two clinical trials. Complete pathologic clearance of all
disease was found at the time of surgery in 8% of the patients
from the current series and in 7% of the patients from the
historical cohort.
Among the 73 G patients who underwent surgical
resection, 60 (82%) completed the postoperative chemoradia-
tion course. Two patients (3%) began the course but could not
complete it due to chest pain during chemotherapy attributed
to 5-fluorouracil cardiac toxicity. The remaining 11 (15%)
patients were unable to receive postoperative therapy; six due
to protracted postoperative recovery and two due to develop-
ment of metastatic disease. One patient declined postopera-
tive treatment, another developed radiation pneumonitis that
precluded postoperative therapy and G, and one patient had
already been taken off study for possible 5-fluorouracil car-
diac toxicity during preoperative treatment.
The median OS and DMC for this G-treated cohort were
24.2 and 20.1 months, respectively. With a median follow-up
among living patients in the G-treated group of 43 months
(range 23–64 months) and 77 months (range 55–95 months) for
the historical cohort not treated with G, the 3-year Kaplan-Meier
outcome estimates for the G and non-G groups are OS 42%
versus 28% (p  0.06) and DMC 40% versus 32% (p  0.33),
respectively (Figures 2A, B). LRC was 76% versus 77% (p 
0.74) and FFR 38% versus 30% (p  0.23).




(n  93) p
Underwent surgical resection (%) 73 (91) 83 (89) 0.66
Unresectable 7 (9) 10 (11)
Surgical procedure (%) 0.026
Trans-thoracic esophagogastrectomy 51 (70) 71 (85)
Trans-hiatal esophagogastrectomy 0 1 (1)
Total gastrectomy 22 (30) 11 (13)
Pathologic response (%) 0.68
Complete response 6 (8) 6 (7)
Partial response 27 (36) 39 (43)
No response 24 (32) 22 (24)
Progressive disease 19 (25) 24 (26)
Not evaluable 4 2
(n  73) (n  83)
Surgical margins (%) 0.79
Positive 8 (11) 8 (10)
Negative 65 (89) 75 (90)
Postoperative mortality (%) 0 4 (5) 0.06
Completed postoperative CCRT (%) 0.54
Resected 60 (75) 65 (70)
Not resected 3 (4) 2 (2) 0.31
CCRT, concurrent chemoradiotherapy; G, gefitinib.
FIGURE 2. Kaplan-Meier projections for the gefitinib and
nongefitinib-treated cohorts. A, Estimated 3-year overall sur-
vival: 42% for the gefitinib group and 28% for the nong-
efitinib group (p  0.06). B, Estimated 3-year distant meta-
static control: 40% for the gefitinib group and 32% for the
nongefitinib group (p  0.33).
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Toxicity
Perioperative chemoradiotherapy-related toxicity for
both the G and non-G treated patients is presented in Table 3.
In general, G-treated patients experienced less mucositis,
myelosuppresion, neutropenic fever, and unplanned hospital-
ization, although rash developed in 42 (52%) and diarrhea in
44 (55%) patients given G. Most G-related toxicity was mild
(grade 1). Only one patient experienced grade 3 diarrhea, four
had grade 2 diarrhea, and one experienced grade 2 skin rash.
Maintenance G was discontinued per protocol for rea-
sons such as delayed postoperative recovery precluding post-
operative chemoradiotherapy or disease progression. Prema-
ture discontinuation of maintenance G for other reasons such
as patient refusal or intolerable toxicity was more common
and was considered to be G intolerance. The G intolerance
rate was 48%. G compliance was assessed by pill counts,
which demonstrated that patients taking G took a median
97% (range 46–100%) of their prescribed pills.
On univariate analysis, significant differences in the
endpoints of interest favored patients with less advanced
pathologic stage disease. The 3-year estimate for OS was
66% for patients with T0-3N0M0 disease, 36% for T0-
3N1M0, and 17% for T4or M1a (p  0.002). Similarly,
3-year DMC (76% versus 30% versus 8%, p 0.0001), LRC
(90% versus 79% versus 34%, p 0.015), and FFR (71%ver-
sus 30% versus 8% p 0.001) were superior among patients
staged T0-3N0M0 at resection compared with T0-3N1M0
and T4 orM1a. If patients with a partial or complete response
to preoperative treatment are compared with those with no
response or progressive disease, an improvement in the
3-year DMC (34% versus 54%, p  0.034) and a trend
toward improved FFR (34% versus 49% p  0.05) and OS
(39% versus 51% p  0.15) were observed.
No differences in outcome were noted in patients who
developed G cutaneous toxicity. However, patients who de-
veloped diarrhea seemed to have improved OS and DMC
(Figures 3A, B). Although diarrhea was the most common
toxicity prompting premature discontinuation of G, there was
no statistical difference in G tolerance or compliance among
patients who experienced diarrhea and those who did not.
DISCUSSION
The predominant pattern of failure after multimodality
treatment of locoregionally advanced esophageal cancer has
been distant metastasis, both at our institution and elsewhere.
This has always suggested to clinical investigators a need for
more effective systemic therapy. Generally, the approach has
been to increase the exposure to systemic chemotherapy, often
FIGURE 3. Kaplan-Meier projections among patients with
and without gastrointestinal toxicity treated with gefitinib. A,
Estimated 3-year overall survival: 52% for patients with diar-
rhea and 30% for those without (p  0.006). B, Estimated
3-year distant metastatic control: 49% for patients with diar-
rhea and 32% for those without (p  0.046).
TABLE 3. Toxicity
Toxicity
Preoperative CCRT Postoperative CCRT
G (n  80) Non-G (n  93) p G (n  63) Non-G (n  67) p
Grades 3–4 nausea/vomiting 1 (1) 0 0.28 0 0 —
Grades 3–4 mucositis 2 (2) 13 (14) 0.007 0 0 —
Serum creatinine 1.5 mg/dl 9 (11) 4 (4) 0.08 3 (5) 2 (3) 0.60
ANC 1000/l 11 (14) 35 (38) 0.001 11 (17) 13 (19) 0.78
Neutropenic fever 4 (5) 16 (17) 0.012 4 (6) 4 (6) 0.93
Platelets 20,000/l 0 1 (1) 0.35 0 1 (1) 0.33
Any unplanned hospitalization 11 (14) 26 (28) 0.023 11 (17) 11 (16) 0.87
ANC, absolute neutrophil count; CCRT, concurrent chemoradiotherapy; G, gefitinib.
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by adding induction chemotherapy to the preoperative chemo-
radiotherapy.19 Although theoretically sound, this approach pro-
longs the duration of therapy and adds not insignificant toxicity
to the overall treatment. We chose a different approach, opting
to address DMC through the use of an easily administered oral
EGFR inhibitor with a favorable toxicity profile. Acknowledg-
ing the limitations of a retrospective, nonrandomized compari-
son, it is of interest that a survival benefit for the G cohort was
suggested, despite similar rates of distant metastasis.
The challenge of appropriately selecting patients for
EGFR targeted therapies may contribute to our findings. Large
phase III clinical studies of unselected patients treated for re-
fractory metastatic non-small cell lung cancer using the oral
EGFR inhibitors G and erlotinib have consistently demonstrated
response rates in the 10 to 15% range.20–22 Asian ethnicity,
female sex, adenocarcinoma histology, lack of tobacco expo-
sure, and sensitizing somatic mutations of the EGFR gene have
been associated with higher rates of response. The relative
homogeneity of the demographic affected by esophageal cancer
makes patient selection for EGFR inhibition according to these
clinical parameters difficult. EGFR sensitizing mutations are
rare and likely unimportant in this disease. The implications of
EGFR overexpression, gene amplification, and K-ras status
have conflicting correlations with drug responsiveness in other
epithelial malignancies and are yet undefined in esophageal
cancer. At present, no clinical or molecular markers for EGFR
inhibitor responsiveness in this disease have been identified.
One clinical parameter consistently associated with
increased response rates is the characteristic cutaneous reac-
tion to EGFR inhibitors.21–24 This observation has been made
in several epithelial malignancies, independent of the type of
EFGR inhibitor used. Although a G rash was not predictive in
our trial, improved outcomes were associated with the devel-
opment of G related diarrhea. Unlike cutaneous toxicity, the
gastrointestinal toxicities of EGFR inhibition and their asso-
ciation with response rates and outcome have not been
described. Cusatis et al. reported a significantly higher rate of
diarrhea and higher serum G levels in patients who possess a
polymorphism of the efflux transporter protein ABCG2. It
could be postulated that our observed improvement in out-
come may relate to increased drug levels and efficacy.23,24
Although the EGFR inhibitors have been regarded as
drugs with a favorable toxicity profile, long-term maintenance
therapy with these agents was not well tolerated in our patient
population. Among patients who remained on the drug with no
evidence of disease recurrence or progression, only 52% were
able to complete the 2-year course of maintenance therapy.
Perhaps, the combination of this drug with our aggressive
multimodality therapy makes the side effect profile less tolerable
as opposed to its use in other settings such as palliative treat-
ment. The inability of patients to complete the course of therapy
may also have contributed to the lack of efficacy noted in
decreasing the incidence of distant metastasis.
The monoclonal antibody cetuximab has demonstrated
synergistic activity with radiation and chemotherapy that has
translated into improved clinical outcomes in other epithelial
malignancies.25–27 However, a similar experience is yet to be
described with G, most widely studied in non-small cell lung
cancer. G maintenance therapy after definitive chemoradiother-
apy in locally advanced non-small cell lung cancer produced
inferior outcomes in the prematurely closed Southwest Oncol-
ogy Group 0023, suggesting that G may result in G1 cell cycle
arrest mitigating the efficacy of systemic therapy.28 It would be
difficult to invoke this phenomenon in our patients, because
locoregional and distant failure rates were similar to our histor-
ical cohort.
The possibility of stage migration must also be addressed
in interpreting our retrospective comparison with historical re-
sults. Despite the similar tumor characteristics and staging be-
tween the G and non-G treated cohorts, integrated PET/CT for
disease staging was not used consistently in the historical cohort,
having been introduced midway during the patient enrollment
period. The improved sensitivity and accuracy of the PET/CT
and EUS combination is well established29–31 and unrecognized
occult metastatic disease at the time of enrollment could have
negatively impacted outcomes in the historical series.
A pathologic complete response (pCR) rate of only 8%
was achieved in this series, after the single cycle of chemo-
therapy and only 30 Gy of radiation. It should be pointed out
that the pCR rate has been frequently observed to predict for
improved survival among patients treated with preoperative
chemoradiation,32–35 leading to recommendations for intensi-
fied efforts to achieve a pCR. This observation, that respond-
ers do better than nonresponders, has been frequently made in
oncology, with only limited implications, and there is reason
for caution when using pCR rates to evaluate the efficacy of
an induction treatment regimen. This end point is influenced
by the timing and accuracy of pathologic response determi-
nation and by the intensity and duration of induction treat-
ment. A pCR is likely to identify patients with more favorable
disease biology, destined to do well independent of the type
of therapy received, and achievement of a pCR may not so
much be the cause of the successful outcome as it is a
reflection of that treatment success. Clinical trials that have
investigated adjuvant therapy after surgical resection and
those that have demonstrated a low pCR rate after preoper-
ative therapy have comparable survival rates as those that
report higher pCR rates.5,7,36 Although pCR rates may facil-
itate reporting of clinical trials, OS is a more accurate reflec-
tion of the efficacy of a treatment regimen.
The increased scrutiny of the economic burden of health
care delivery appropriately raises the issue of the financial
implications of administering this multimodality treatment reg-
imen. Apart from the obvious costs of hospitalization, drug, and
drug administration, other incurred expenses not easily quanti-
fied include the cost of transportation to receive care, copay-
ments, and income lost from missed days at work. At our
institution, the delivery of chemoradiotherapy is facilitated
through a dedicated inpatient chemotherapy service. Although
no formal cost analysis of this regimen has been performed, it
avoids placement of indwelling catheters, decreases transporta-
tion costs for twice daily radiation, and allows for inpatient
supportive care during chemoradiotherapy, which may avoid
unplanned hospitalizations for symptom control. Reducing the
cost of cancer care is an integral aspect of improving its avail-
ability and outcomes. In addition to focusing efforts toward
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appropriate patient selection for expensive new drugs, a com-
prehensive examination of the financial consequences of a pro-
posed treatment regimen is critical.
In conclusion, although the EGFR inhibitor G did not
reduce the incidence of distant metastases when incorporated
into our multimodality therapy for locally advanced esopha-
geal cancer, the possible impact on survival is intriguing.
Patient tolerance of a 2-year course of maintenance therapy
was suboptimal. Although further investigation into the use
of these agents in esophageal carcinoma is of considerable
interest, identification of specific patient and molecular char-
acteristics associated with possible drug activity is critical.
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